Trials / Unknown
UnknownNCT04582981
Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer
A Randomized, Controlled Phase II Clinical Trial of Fruquintinib Combined With Raltitrexed Versus Fruquintinib Monotherapy in Patients With Advanced Colorectal Cancer Who Had Failed Second-line or Above Standard Chemotherapy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 136 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A randomized, controlled phase II clinical trial of Fruquintinib combined with Raltitrexed versus Fruquintinib monotherapy in patients with advanced colorectal cancer who had failed second-line or above standard chemotherapy
Detailed description
This study plans to evaluate the clinical benefits of fruquintinib combined with raltitrexed compared with fruquintinib single drug treatment in patients with advanced colorectal cancer who have failed second-line or above treatment, in order to explore the rationality of this strategy with chemotherapy + targeted combination therapy and obtain the relevant survival and safety data. A total of 136 patients were planned to be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fruquintinib and raltitrexed | Fruquintinib 5mg qd plus raltitrexed 2mg/m2, q2w |
| DRUG | Fruquintinib | Fruquintinib 5mg qd monotherapy |
Timeline
- Start date
- 2020-09-28
- Primary completion
- 2023-06-01
- Completion
- 2023-12-01
- First posted
- 2020-10-12
- Last updated
- 2021-10-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04582981. Inclusion in this directory is not an endorsement.